Jennewein Biotechnologie

From the laboratory into the world

Living the impossible

When Dr. Stefan Jennewein began pursuing his vision of using biotechnology to manufacture human milk oligosaccharides (HMO’s) for infant nutrition, he was told that realizing this goal would be impossible for three reasons. First, biotechnology would never be able to produce HMO’s at the multi-hundred-ton scale, which is necessary for infant food applications. Second, even if these scales could be achieved, production would be far too expensive for the infant food market to bear. And third, in the highly unlikely event that these production obstacles could be overcome, the product would never be approved by the regulators.

In November 2015, Jennewein Biotechnologie received market approval from the FDA for its first product, 2′-fucosyllactose, for applications in infant and toddler nutrition.

In summer 2016, the world’s first infant formula containing the HMO 2′-fucosyllactose went on sale in the US.

Finally, on 25 September 2017, the European Commission voted in favor of the market approval of Jennewein’s 2′-fucosyllactose in the European Union, 4 years after the dossier was submitted (and in the wake of that further approvals in countries such as Israel, Singapore and The Philippines have followed).

At long last, one of the most beneficial ingredients in human nutrition is now available to all infants, including those that cannot be breast fed.

Jennewein Biotechnology – Living the Impossible.